MarginsXMarginsX
Home › Markets › Health Care › QNTM

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)

QNTM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.44
-10.56% on the day
Market cap
$12.2M
Nano cap
Revenue
No annual revenue filed since the period ending 2019-12-31
Net income
No annual revenue filed since the period ending 2019-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerQNTM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001771885

Financials

No annual revenue filed since the period ending 2019-12-31.

Warning signs

Cash runway
2.8 months
$1.9M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed March 26, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Based on management's expectations of future net cash flows, management has applied judgement that there is no material uncertainties related to events or conditions that may cast substantial doubt on the Company's ability to continue as a going concern."
20-F 2026-03-26
Cash and burn$1.9M cash; operating cash flow -$2.1M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-65 on 2024-08-15Source 2024-08-15
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMNP LLP, Mississauga, CanadaPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filedNot filed-$8.2M$1.9M$1.3MNeeds four quarters20-F 2026-03-26
FY 2024
2024-12-31
Not filedNot filed-$6.9M$6.0M$619KNeeds four quarters20-F 2026-03-26
FY 2023
2023-12-31
Not filedNot filed-$10.8M$2.8MNo debt tagsNeeds four quarters20-F 2026-03-26
FY 2022
2022-12-31
Not filed-$23.6M-$28.3M$17.0MNo debt tagsNeeds four quarters20-F 2023-03-31
FY 2021
2021-12-31
Not filed-$35.3M-$20.7M$35.3MNo debt tagsNeeds four quarters20-F 2023-03-31
FY 2020
2020-12-31
Not filed-$31.8M-$19.1M$17.5MNo debt tagsNeeds four quarters20-F 2023-03-31
FY 2019
2019-12-31
Not filed-$39.1M-$13.7M$6.0MNo debt tagsNeeds four quarters40-F 2021-03-17

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-23.5%
1 month-44.3%
3 months-50.2%
Year to date-77.9%
1 year-79.1%
From 52-week high-85.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M
BIVIBioVie Inc.$1.08-4.42%$11.6M
DAREDare Bioscience Inc.$0.5842-11.13%$11.5M
KYNBKyntra Bio Inc.$3.20-8.31%$13.0M
CMMBChemomab Therapeutics Ltd. American Depositary Share$1.62+5.88%$13.0M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
RADXRadiopharm Theranostics Limited$0.7676+1.00%$11.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier